S1086
Clinical – Upper GI
ESTRO 2026
Kingdom. 3 Department of Clinical Oncology, James Cook Cancer Institute, The James Cook University Hospital, Middesbrough, United Kingdom. 4 Department of Clinical Oncology, Queen’s Cancer Centre, Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom Purpose/Objective: Radiation-induced strictures (RIS) can occur in patients with localised oesophageal cancer (OC) treated with radical radiotherapy with or without concurrent chemotherapy (RT±C). The incidence, risk factors and outcomes associated with RIS remain poorly defined. Material/Methods: This single-centre retrospective study evaluated outcomes of patients who developed RIS following RT±C for OC between January 2019 and December 2020. Results: Of 176 patients completing RT±C, 66% were male with a median age of 73 years (43–92). Tumour staging was T1 9%, T2 11%, T3 68%, T4 7% and Tx/unspecified 5%. Nodal staging was N0 48%, N1 44%, N2 7% and N3 1%. Histology included adenocarcinoma 55%, squamous cell carcinoma 44% and other 1%. Tumour location was upper 7%, mid 27%, distal 44%, gastro- oesophageal junction (GOJ) 20% and other 2%. Median tumour length was 5 cm (1–12 cm).Median overall survival (mOS) for the cohort was 20.6 months (m) [95% CI 18.7–27.0]. One hundred patients (57%) received chemoradiotherapy 50 Gy/25 fractions (#) with mOS 37.1 m [95% CI 23.4–59.3]. Fifty-five (31%) received RT 50 Gy/20# (mOS 17.6 m [95% CI 9.9–20.1]) and 21 (12%) received 50 Gy/16# (mOS 16.7 m [95% CI 8.4–19.3]).Sixty-one patients (35%) developed a stricture, of which 33 (54%) were malignant, representing recurrent or residual disease, and 28 (46%) were histologically benign RIS. Among benign RIS, median time from RT completion to stricture onset was 3.9 m [95% CI 3.1–4.9]. Tumour stage, nodal stage, RT fractionation, age, sex, smoking status, baseline dysphagia, need for nasogastric feeding and medication history (bisphosphonates, PPIs, steroids, NSAIDs) were not predictive of RIS development on univariate analysis. Twenty benign RIS (71%) were endoscopically non-traversable; 20 (71%) underwent balloon dilatation, and 4 (14%) developed recurrent disease. The mOS for patients with RIS was 46 m [95%
collaborative studies are warranted to better characterise RIS, identify potential risk factors, and inform development of consensus guidelines. Keywords: oesophageal radiotherapy, strictures, late effect
Digital Poster Highlight 2561
Preliminary clinical outcomes from a single- institution phase II study of stereotactic body radiotherapy for hepatocellular carcinoma in Chile Pablo Munoz-Schuffenegger 1,2 , Paula Rivera 3 , Cristobal Vargas 4 , Nancy Solis 3 , Francisco Barrera 3 , Luis Antonio Diaz 3 , Alejandro Soza 3 , Luis Meneses 5 , Paula Reyes 4 , Gabriela Antunez 4 , Rodrigo El Far 4 , Cecilia Besa 5 , Alvaro Huete 5 , Nicolas Jarufe 6 , Sebastian Mondaca 7 , Bruno Nervi 7 , Eugenio Vines 1 , Marco Arrese 3 1 Radiation Oncology Unit, Department of Hematology - Oncology, Pontificia Universidad Catolica de Chile, Santiago, Chile. 2 CECAN, Centro para la Prevencion y el Control del Cancer, Santiago, Chile. 3 Department of Gastroenterology, Pontificia Universidad Catolica de Chile, Santiago, Chile. 4 Radiation Oncology Unit, Department of Hematology – Oncology, Pontificia Universidad Catolica de Chile, Santiago, Chile. 5 Department of Radiology, Pontificia Universidad Catolica de Chile, Santiago, Chile. 6 Department of Digestive Surgery, Pontificia Universidad Catolica de Chile, Santiago, Chile. 7 Department of Hematology – Oncology, Pontificia Universidad Catolica de Chile, Santiago, Chile Purpose/Objective: Stereotactic body radiotherapy (SBRT) is an effective locoregional treatment for patients with hepatocellular carcinoma (HCC) who are not eligible for other treatments, as established in recent years by multiple clinical guidelines. To date, prospective data from Latin America are scarce. We report an interim analysis from a prospective, single-institution phase II study designed to validate clinical outcomes of SBRT for HCC and to enable future biomarker discovery. Material/Methods: An interim analysis of an ongoing prospective, IRB- approved, single-institution, phase II study aiming at validating previously published outcomes of SBRT for HCC in previous prospective studies. Patients were eligible if they had radiologically or biopsy-confirmed HCC, liver function A5 to B8 as per the Child-Pugh score (CPT), and were ineligible for other locoregional therapies due to disease extent, prior treatment failure, medical comorbidities, or difficulty with access. Biospecimen collection for biomarker analysis and quality of life assessment are ongoing and not included in this interim report. Data cutoff was October 16, 2025.
CI 21.7–71.7]. Conclusion:
The rate of benign RIS was 16%, typically presenting within six months of completing RT. Survival outcomes following radical-intent RT±C are encouraging and likely reflect advancements in RT planning and delivery. No clear risk factors for RIS development were identified. Further work is needed to optimise endoscopic management, and multi-centre
Made with FlippingBook - Share PDF online